Today, the World Anti-Doping Agency (WADA) published the revised Guideline for Therapeutic Use Exemption (TUE) Enquiries by Accredited Laboratories, version 3.0, dated November 2019. This version takes effect immediately.
The Guideline assists Laboratories in determining how to proceed in the case of Presumptive Adverse Analytical Findings exclusively for the substances and drug classes listed in Article 188.8.131.52.4.7.3 of the .
This specifically applies to: Amphetamine, Methylphenidate, Beta-2 Agonists, Diuretics, Glucocorticoids or Beta-blockers; or, for any other Prohibited Substance or Prohibited Method that’s use has been declared by an athlete on a Doping Control Form.
The Guideline also assists Laboratories regarding enquiries with relevant Testing Authorities and/or Results Management Authorities about the existence of approved TUEs before performing confirmation analyses.
Should you have any questions regarding this Guideline, please do not hesitate to contact .